ArticleOncology letters2018
Role of YAP in lung cancer resistance to cisplatin.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- An Overview of Cellular and Molecular Determinants Regulating Chemoresistance in Pleural Mesothelioma.Cancers · 2025Review
- Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway.Cancer cell international · 2024Article
- Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers.Cancer gene therapy · 2024Review
- Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells.Free radical biology & medicine · 2024Article
- scRNA-seq revealed high stemness epithelial malignant cell clusters and prognostic models of lung adenocarcinoma.Scientific reports · 2024Article
- Role of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer.International journal of biological sciences · 2024Review
- YAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer.International journal of molecular sciences · 2023Review
- YAP/TAZ: Molecular pathway and disease therapy.MedComm · 2023Review
- Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.PloS one · 2023Article
- Substrate stiffness reduces particle uptake by epithelial cells and macrophages in a size-dependent manner through mechanoregulation.Nanoscale · 2022Article
- PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.Oncogene · 2022Article
- Lappaol F, an anticancer agent, inhibits YAP via transcriptional and post-translational regulation.Pharmaceutical biology · 2021Article
- Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent manner.Oncology letters · 2021Article
- Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.Oncogene · 2021Article
- Inhibitors Targeting YAP in Gastric Cancer: Current Status and Future Perspectives.Drug design, development and therapy · 2021Review
- Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy.Cell & bioscience · 2020Article
- The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).Cancers · 2020Review
- Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy.Photochemistry and photobiology · 2020Article
- Apoptosis-related gene expression can predict the response of ovarian cancer cell lines to treatment with recombinant human TRAIL alone or combined with cisplatin.Clinics (Sao Paulo, Brazil) · 2020Article
- YAP/TAZ Signaling and Resistance to Cancer Therapy.Trends in cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yes-associated protein (YAP) serves a critical role in the initiation and progression of a variety of types of cancer via modulating the expression of genes involved in cell proliferation and the downregulation of apoptosis. Recent studies have suggested that YAP is responsible for the development of drug resistance and cancer metastasis and recurrence. However, the association between YAP and chemoresistance in lung cancer, particularly in lung cancer stem cells (LCSCs) remains largely unknown. In the current study, lung cancer cell spheres were established using the A549 cell line, which demonstrated stem cell properties. It was revealed that YAP was overexpressed in lung cancer spheres compared with normal A549 adherent cells and was associated with enhanced cisplatin (CDDP) resistance. Knockdown of YAP effectively sensitized the adherent A549 and tumor spheres to CDDP treatment and resulted in enhanced cell death. These results suggest that YAP serves a critical role in LCSCs drug resistance and YAP targeting could become a promising adjuvant to current the chemotherapy for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.